Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Carcinoma, Hepatocellular · Hepatocellular Cancer · Hepatocellular Carcinoma · Unresectable Hepatocellular Carcinoma · Liver Neoplasms · Advanced Hepatocellular Carcinoma · Metastatic Hepatocellular Carcinoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 138 (planned)
- Started
- Dec 1, 2025
- Main results expected
- Oct 18, 2027
- Fully finished
- Oct 17, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With Adverse Events
Measured over: Through end of study and up to approximately 24 months
Phase 1b: Number of participants with Dose limiting toxicities (DLT)
Measured over: Through 90 days after the last dose of study intervention; Approximately 24 months
Phase 2: Confirmed Overall Response Rate (ORR) using RECIST 1.1 as assessed by investigator
Measured over: Approximately 24 months
Phase 2: Recommended dose of PF-08634404 in combination with ipilimumab
Measured over: Approximately 24 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07227012 · record last updated 2026-10-08 · checked 2026-11-09 15:36 UTC